Renal Biomarker
Market
Share, Global Trends,
Analysis, Research, Report,
Opportunities,
Segmentation and Forecast,
2016 – 2026
Future Market Insights
www.futuremarketinsights.com
[email protected]
Future Market Insights (FMI) is a premier provider of syndicated research reports, custom research reports, and consulting
services. We deliver a complete packaged solution, which combines current market intelligence, statistical anecdotes,
technology inputs, valuable growth insights, aerial view of the competitive framework, and future market trends.
We provide research services at a global as well as regional level; key regions include GCC, ASEAN, and BRIC.
Our offerings cover a broad spectrum of industries including Chemicals, Materials, Energy, Technology, Healthcare, and
Retail.
We have a global presence with delivery centers across India specializing in providing global research reports and country
research reports. FMI is headquartered out of London, U.K., with a state-of-the-art delivery center located in Pune, India. We
combine our knowledge and learning from every corner of the world to distill it to one thing – the perfect solution for our
client.
Research
Capabilities




Customized
Research
Customized Research
Syndicated Research
Investment Research
Social Media Research
Sector Coverage





Automotive and Transportation

Electronics, Semiconductor, and ICT

Retail and Consumer Products

Industrial Automation and Equipment

Healthcare, Pharmaceuticals & Medical Devices
Subscription Information
Syndicated
Research
For detailed subscription information please contact
Investment
Research
T: +44 (0) 20 7692 8790 | D: +44 20 3287 4268
Social Media
Research
Hari. T (Sr. Manager - Global Business Development)
Email: [email protected]
Chemicals & Materials
Food and Beverages
Services and Utilities
Energy, Mining, Oil, and
Gas
Report
Description
Report Description
Currently diagnosis of many diseases is obligated to detection of several disease specific markers
referred to as biomarker. European Medical Agency defines biomarkers as measurable
characteristics that reflect physiological, pharmacological progression of a disease. Renal
diseases including acute kidney injury, chronic kidney disease, glomerular disease, preeclampsia
etc., have a high mortality and morbidity rate and are characterized by the rapid or gradual loss
of kidney function resulting into serous clinical implications. The gold standard for diagnosis of
renal injury i.e. routine estimation of serum creatinine lack sufficient sensitivity for early
detection of injury and are not specific for the site of injury having limited clinical utility. In case
of diseases such as acute kidney disease and chronic kidney disease creatinine takes several days
to reach the steady state and up to 50 % of the kidney function may be lost before the serum
creatinine begins to rise during the kidney injury. Hence, there is an impending need of
development of specific biomarker that can detect the renal disorders at the earliest which helps
in timely preventive or more effective treatments for management of renal disorders. A number
of emerging biomarkers are currently being developed in order to help early diagnose and
prevent catastrophic outcomes of various renal disorders in clinical practice. The most promising
biomarkers of acute kidney injury (AKI) for clinical use include a plasma panel (NGAL and cystatin
C) and a urine panel (NGAL, Il-18 and KIM-1).The major factors fuelling the need for
development of novel renal biomarkers includes increasing prevalence of various kidney
disorders, along with growing incidence of other chronic disorders such as diabetes, obesity and
hypertension, as these diseases are often associated with the gradual loss of kidney function.
Report
Description
Report Description
Renal Biomarker Market: Drivers and Restraints
The incidence of chronic kidney diseases (CKD) is increasing rapidly in aging population. The
National Institute of Diabetes and Digestive and Kidney Disease estimates that the prevalence of
CKD in people aged 65 and older doubled between 2000 and 2008. CKD continues to be a major
cause of lost productivity, physician visits and hospitalizations globally. In addition, factors such
as increasing prevalence of diabetes and high blood pressure and cardiovascular disorders also
contributes towards the exponential market growth of renal biomarkers in the near future.
American kidney Fund, 2012 estimated diabetes as one of the leading cause of kidney failure
accounting for 44% of the new cases. Furthermore, increasing investments in research and
development will further boost the renal biomarker market growth globally as a large number of
renal biomarkers are currently being to assess the safety of new drugs.
Request Free Report Sample@ http://www.futuremarketinsights.com/reports/sample/rep-gb1731
However lack of awareness and tight regulations scenario in developing countries is expected to
restrain the renal biomarker market growth in the near future.
Renal Biomarker Market: Segmentation
Report
Description
Report Description
The global renal biomarker market has been classified on the basis of marker type, application,
end user and geography.
Based on marker type, the global renal biomarker market is divided into following:
•
Creatinine
•
Blood Urea Nitrogen
•
Cystatin C
•
Neutrophil Gelatinase-Associated Lipocalin (NGAL)
•
Kidney Injury Molecule-1 (KIM-1)
•
Retinol Binding Protein (RBP) Alanine-aminopeptidase (Ala-AP)
•
Others
Based on the diagnostic tests, the global renal biomarker is divided into following:
•
•
•
•
•
Radioimmunoassay (RIA)
Enzyme Linked Immunosorbent Assay (ELISA)
Chemiluminescent Enzyme Immunoassay (CLIA)
Particle-Enhanced Turbidimetric Immunoassay (PETIA)
Liquid Chromatography-Mass Spectrometry
Based on the end user type, the global renal biomarker is divided into following:
Report
Description
Report Description
•
•
•
Hospitals
Research Centers
Specialty Diagnostic Clinics
Renal Biomarker Market: Overview
Biomarkers are defined to be valuable tools in clinical diagnostics as well as in therapeutic drug
discovery and development. In order to improve the care of patients with renal disorders there
is a need to develop novel renal biomarkers. However, widespread availability of enabling
technologies such as functional genomics and proteomics has also accelerated the rate of novel
biomarker discovery for renal diseases globally. Additionally FDA clearance and regulatory
approval of revolutionary diagnostic assays are also expected to create the revenue traction in
global renal biomarker market in the near future.
Request For TOC@ http://www.futuremarketinsights.com/toc/rep-gb-1731
Renal Biomarker Market: Regional Overview
Region wise, the global wide filed imaging systems market is classified into regions namely,
North America, Latin America, Western Europe, Eastern Europe, Asia-Pacific, Japan, Middle East
and Africa.North America leads the global renal biomarker market followed by Europe.
Report
Description
Report Description
Growing prevalence of various renal disorders, growing investment in R & D and increased FDA
approvals are expected towards the revenue traction in North America. Worldwide market for
renal biomarkers is still evolving and major drug development firms and various companies need
to work in close coordination with each other in order to develop unique biomarkers for the
management of various renal disorders.
Smart Contact Lens: Key Players
Some of the key players in global wide filed imaging systems market are Abbott Diagnostics, F.
Hoffmann-La Roche AG, Beckman Coulter Inc., Siemens Healthcare Diagnostics Inc., Thermo
Fisher Scientific Inc., Astute Medical Inc., Alere Inc., bioMérieux SA and Randox Laboratories Ltd.
Thank You!
To know more about us, please visit our website:
www.futuremarketinsights.com
For sales queries or new topics email us on:
[email protected]
For other queries contact:
Future Market Insights: 616 Corporate Way, Suite 2-9018,
Valley Cottage, NY 10989, United States
T: +1-347-918-3531 | D: +1-845-579-5705